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Abstract The B-chain homodimer isoform of platelet-derived 
growth factor (PDGF) binds with high affinity both to ~- and to 
IS-receptors. In order to localize amino acid residues in PDGF- 
BB of differential importance for the binding to the two 
receptors, PDGF-BB mutants were analyzed in which single 
amino acid residues were changed to alanine residues. We found 
that Phe-118 in loop 1 of the PDGF B-chain is crucial for 
binding to both receptors, and that the surrounding amino acids, 
Asn-117 and Leu-119, appear to be important primarily for 
binding to the [~-receptor. In contrast, Lys-161 in loop 3 was 
found to be more important for binding to a-receptors than 
receptors. Previous studies have shown that the receptor binding 
epitopo of PDGF-BB is composed mainly of loops 1 and 3; the 
findings of the present study show that the cz- and IS-receptors 
interact with different amino acid residues in these regions. 
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I. Introduction 
Platelet-derived growth factor (PDGF) occurs as homo- or 
heterodimeric soforms of A- and B-polypeptide chains [1]. 
The three-dimensional structure of PDGF-BB has recently 
been determined [2]; the two disulfide-bonded subunits are 
arranged in an antiparallel manner, each of which contains 
three intramolecular disulfide bonds arranged in a tight knot- 
like structure and two twisted [3-sheets. Thus, each subunit 
consists of two loops (loops 1 and 3) pointing in one direction 
and another (loop 2) pointing in the other direction. Muta- 
tional analyses have revealed that amino acid residues in loops 
1 and 3 are important for receptor binding [3-6]. Also loop 2, 
which is located close to loops 1 and 3 in the other subunit in 
the dimer, is important for receptor binding, in particular for 
binding to the I~-receptor [4,7]. 
PDGF exerts its cellular effects by binding to two structu- 
rally similar protein tyrosine kinase receptors [8,9]. The a- 
receptor binds both PDGF A- and B-chains, whereas the 13- 
receptor binds only the B-chain with high affinity. Ligand 
binding induces receptor dimerization. Activation of either 
c~- or I]-receptors leads to stimulation of cell growth. How- 
ever, on human fibroblasts and smooth muscle cells only the 
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[~-receptor mediates a stimulatory effect on chemotaxis; acti- 
vation of the c~-receptor in fact inhibits chemotaxis of these 
cells [10-13]. 
The stimulatory effect of PDGF-BB and PDGF-AB on 
chemotaxis of fibroblasts and smooth muscle cells, mediated 
via the PDGF [3-receptor, will thus be modulated by inhibi- 
tory signals via the a-receptor present on the same cells [14]. 
A PDGF B-chain mutant which has lost the ability to bind to 
the a-receptor but retains the I~-receptor binding activity 
would thus be expected to have an increased chemotactic ac- 
tivity. The present study was undertaken with the aim of 
identifying amino acid residues in PDGF-BB with a differen- 
tial role in binding to the two PDGF receptors. 
2. Materials and methods 
2.1. Construction of cDNAs encoding PDGF mutants 
cDNA encoding the PDGF-Bstop mutant in which codon 191 in 
the PDGF B-chain was mutated to a stop codon have been described 
[15]. Single amino acid residue mutants of PDGF-Bstop with amino 
acid residues Nl17, FlI8, Ll19, V159, R160, K161, K162 changed to 
alanine residues were carried out using the Altered Sites in vitro mu- 
tagenesis system (Promega). 
2.2. Expression of recombinant proteins 
The DNA constructions encoding wild-type or mutant PDGF 
chains were cloned into the pSV7d expression vector and transfected 
into COS cells as described [15], using 15 ~tg of plasmid DNA and 
0.5-1 x 106 cells in 60 mm culture dishes. Serum-free conditioned 
media were collected 3 days after transfection. 
2.3. Receptor binding analysis of recombinant proteins 
Binding analysis was performed as described by Andersson et al. 
[7]. Briefly, conditioned media from transfected COS cells were de- 
salted and concentrated 10-fold using a reversed-phase C4 column. 
The amount of PDGF recombinant proteins was determined by a 
radioimmunoassay using a rabbit antiserum against PDGF-BB [16]. 
The amount of PDGF ]3-receptor binding activity was determined by 
analyzing serial dilutions of conditioned media with regard to their 
ability to compete with 125I-PDGF-BB for binding to human foreskin 
fibroblasts (AG 1518) on which the c~-receptor had been downregu- 
lated by prior incubation of the cells with 50 ng/ml of PDGF-AA for 
30 rain at 37°C [17]. The a-receptor binding capacity was analyzed 
according to the ability to compete with 12~I-PDGF-AA for binding 
to human fibroblasts. 
3. Results 
Previous studies have shown that Phe-ll8 in loop 1 is im- 
portant for receptor binding [18], and that the amino acid 
residues in the A-chain corresponding to the conserved Lys- 
161 and Lys-162 are important for binding to the PDGF a- 
receptor [19]. In our attempts to identify amino acid residues 
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Fig. 1. Schematic illustration of the PDGF B-chain structure. The 
amino acid residues in the loop 1 and 3 regions that were replaced 
in the PDGF B-chain mutants are marked with circles. 
with different importance for binding to a- and 13-receptors, 
we therefore focused on conserved amino acid residues in the 
regions around these amino acid residues. 
A series of expression vectors coding for wild-type PDGF 
B-chain and B-chain mutants (schematically shown in Fig. 1) 
was prepared and used for transient expression in COS cells. 
The abilities of the mutant PDGF molecules to compete for 
binding of 12~I-PDGF-AA and 125I-PDGF-BB to a- and 13- 
receptors, respectively, were determined and compared to that 
of wild-type PDGF-BB. In order to achieve efficient secretion 
of wild-type PDGF-BB and PDGF-BB mutants, vector con- 
structs were used coding for truncated molecules lacking the 
basic motif in the C-terminus of the PDGF B-chain which 
mediates retention intracellularly and to the extracellular ma- 
trix [15,20,21]. 
A mutant with Phe- l l8 replaced with an alanine residue 
was found to have a more than 10-fold lower ability to bind 
to a- as well as to 13-receptors (Fig. 2). Mutation of the 
neighbouring Asn-117 to an alanine residue had no effect on 
binding to the a-receptor but decreased the binding to 13-re- 
ceptors about 4-fold. The L119A mutant showed 2-fold lower 
binding to the a-receptor and 4-fold lower binding to the 13- 
receptor. In conclusion, these mutations in loop 1 establish an 
important role for Phe-118 in the interaction with both a- and 
13-receptors, and show that the neighbouring residues Leu-119 
and Asn-117 are important primarily for binding to the 13- 
receptor. 
In the loop 3 region, mutation of Val-159, Arg-160 or Lys- 
162 to alanine residues had no effect on binding to either a- or 
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Fig. 2. PDGF receptor competing activities of PDGF-BB loop 1 mutants. Concentrated conditioned media from mock transfected COS cells 
(O), or COS cells transfected with wild-type PDGF-B (©), or Nll7A (11), Fl l8A (D), or Lll9A (z~) PDGF-B mutants, were analysed for their 
abilities to compete with the binding of 125I-PDGF-AA to PDGF a-receptors (A), and with the binding of 12sI-PDGF-BB to PDGF 13-recep- 
tors (B). The concentrations of PDGF-BB mutants in the conditioned media were determined by a radioimmunoassay, nd are expressed as 
PDGF-BB equivalents. 
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Fig. 3. PDGF receptor competing activities of PDGF-BB loop 3 mutants. Concentrated conditioned media from mock transfected COS cells 
(O), or COS cells transfected with wild-type PDGF-B (©), or VI59A (A), R160A (A), K161A (la), or K162A (U) PDGF-B mutants, were ana- 
lysed for their abilities to compete with the binding of 125I-PDGF-AA to PDGF s-receptors (A), and with the binding of 125I-PDGF-BB to 
PDGF ~l-receptors (B). The concentrations of PDGF-BB mutants were determined as described in the legend to Fig. 2. 
showed about 2-fold lower I]-receptor binding activity and 
about 5-fold lower or-receptor binding activity (Fig. 3). At- 
tempts were made to find other mutants with an even larger 
difference in their abilities to interact with a- and I]-receptors. 
However, a double mutant K160A/K161A was found to have 
the same characteristics as the K161A mutant, whereas a 
K161D mutant showed more than 10-fold reduction, as com- 
pared to wild type, in binding to both ct- and I]-receptors 
(data not shown). 
4. Discussion 
We have shown in this communication that a region around 
Phe- l l8  in loop 1 of the PDGF B-chain is important for 
Table 1. Summary of binding characteristics of PDGF B-chain mu- 
tants 
a-Receptor binding ~l-Receptor binding 
wt PDGF B-chain +++ +++ 
N117A mutant +++ ++ 
F118A mutant - 
L119A mutant (+)++ ++ 
V159A mutant +++ +++ 
RI60A mutant +++ +++ 
K161A mutant + ++ 
K162A mutant +++ +++ 
The abilities of wild-type, as well as mutant forms of PDGF B-chain 
to inhibit the binding of 125I-PDGF-AA and 125I-PDGF-BB to PDGF 
a- and 13-receptors, were determined. +++, less than 2-fold decreased 
receptor binding compared to wild-type B-chain; ++, 2--4-fold de- 
creased receptor binding; +, 4-10-fold decreased receptor bind- 
ing; , more than 10-fold decreased receptor binding. 
binding to the PDGF a-receptor, and to an even larger extent 
to the I]-receptor. In contrast, Lys-161 in loop 3 is more im- 
portant for binding to a-receptors than to I~-receptors. Our 
results thus demonstrate a differential importance of certain 
amino acid residues in PDGF-BB for binding to the two 
PDGF receptors. The receptor binding properties of the 
PDGF-BB mutants studied are summarized in Table 1. 
PDGF-AA binds exclusively to or-receptors and does not 
activate I]-receptors. However, there is no known ligand which 
activates I]-receptors without also activating a-receptors. In 
view of the inhibitory effect of a-receptors on chemotaxis of 
fibroblasts and smooth muscle cells, a mutated PDGF mole- 
cule activating ~l-receptors but not a-receptors could have a 
greater stimulatory effect than wild-type PDGF,  e.g. on 
wound healing which involves stimulation of cell growth, ma- 
trix production as well as chemotaxis. The finding in the pre- 
sent work that Lys-161 is of greater importance for binding to 
a-receptors than to ~]-receptors provides a first step towards 
the design of PDGF B-chain mutants which exclusively bind 
to the ~l-receptor of PDGF.  
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